Advertisement

Infectious Diseases and Therapy

, Volume 5, Issue 3, pp 363–365 | Cite as

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting

  • Daniel H. DeckEmail author
  • Jennifer M. JordanEmail author
  • Thomas L. Holland
  • Weihong Fan
  • Matthew A. Wikler
  • Katherine A. Sulham
  • G. Ralph Corey
Open Access
Erratum
  • 574 Downloads

Erratum to: Infect Dis Ther (2016) DOI 10.1007/s40121-016-0119-9

Following publication of the aforementioned article, the authors noted a minor error in Table 1 and two small errors in Table 2. In Table 1, the Eron Class III Clinical Criteria should read CrCl <30 mL/min or on dialysis, not CrCl <20 mL/min. In Table 2, Distribution of SOLO patients in modified Eron Classes I–III, the number of outpatients receiving vancomycin (VAN) in Class I should be 111, not 11. The total number of inpatients (Class I–III) was omitted, n = 1143 (59.8%).
Table 1

Clinical criteria used to define modified Eron Classes I–IV

Eron class

Clinical criteria

IV

Bacteremia (positive blood culture); or

Absolute total neutrophils count <500

III

Meeting SIRS criteria

CrCl <30 mL/min or on dialysis

ALT/AST >10-times ULN

Heart rate >90/min, breath rate >20/min, or systolic BP <90 mmHg; or

Cancer

II

Age ≥75 years old

Glucose >11.1 mmol/L

Congestive heart failure at the randomization

30 mL/min < CrCl <60 mL/min

Hepatitis (excluding AST/ALT >10-times ULN)

Peripheral vascular disease

Diabetes mellitus

Fever (temperature >38.0 °C); or

BMI ≥30 kg/m2

I

For the patients who didn’t meet Classes II–IV

ALT alanine transaminase, AST aspartate transaminase, BMI body mass index, BP blood pressure, CrCl creatinine clearance, SIRS systemic inflammatory response syndrome, ULN upper limit of normal

Table 2

Distribution of SOLO patients in modified Eron Classes I–III (mITT population, n = 1959)

 

Class I

Class II

Class III

Total (Class I–III)

SOLO mITT (n = 1959)

520 (26.5%)

790 (40.3%)

600 (30.6%)

1910

Inpatients, n (%)

301 (57.9%)

431 (54.6%)

411 (68.5%)

1143 (59.8%)

ORI, n

144

224

203

571

VAN, n

157

207

208

572

Outpatients, n (%)

219 (42.1%)

359 (45.4%)

189 (31.5%)

767 (40.2%)

ORI, n

108

182

89

379

VAN, n

111

177

100

388

mITT modified intent-to-treat, ORI oritavancin, VAN vancomycin

Notes

Open Access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Copyright information

© The Author(s) 2016

Authors and Affiliations

  • Daniel H. Deck
    • 1
    Email author
  • Jennifer M. Jordan
    • 1
    Email author
  • Thomas L. Holland
    • 2
  • Weihong Fan
    • 1
  • Matthew A. Wikler
    • 1
  • Katherine A. Sulham
    • 1
  • G. Ralph Corey
    • 2
  1. 1.The Medicines CompanyParsippanyUSA
  2. 2.Duke University HospitalDurhamUSA

Personalised recommendations